These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28589643)

  • 1. Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil.
    Vieira PCM; Lamarão LM; Amaral CEM; Corrêa ASM; de Lima MSM; Barile KADS; de Almeida KLD; Sortica VA; Kayath AS; Burbano RMR
    Transfusion; 2017 Aug; 57(8):1968-1976. PubMed ID: 28589643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil.
    Corrêa ASM; Lamarão LM; Vieira PCM; de Castro RBH; de Almeida NCC; de Castro JAA; de Lima MSM; Palmeira MK; Meireles ALLP; Burbano RR
    PLoS One; 2018; 13(12):e0208414. PubMed ID: 30566494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.
    Weusten JJ; van Drimmelen HA; Lelie PN
    Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C; Araújo F
    Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.
    Velati C; Romanò L; Piccinini V; Marano G; Catalano L; Pupella S; Facco G; Pati I; Tosti ME; Vaglio S; Grazzini G; Zanetti A; Liumbruno GM
    Blood Transfus; 2018 Sep; 16(5):422-432. PubMed ID: 30036178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.
    Zou S; Dorsey KA; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY; Stramer SL
    Transfusion; 2010 Jul; 50(7):1495-504. PubMed ID: 20345570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Kleinman SH; Vamvakas EC
    Transfusion; 2007 Feb; 47(2):316-25. PubMed ID: 17302779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.
    Soldan K; Barbara JA; Ramsay ME; Hall AJ
    Vox Sang; 2003 May; 84(4):274-86. PubMed ID: 12757501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.
    Kim MJ; Park Q; Min HK; Kim HO
    BMC Infect Dis; 2012 Jul; 12():160. PubMed ID: 22817275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil.
    Barreto CC; Sabino EC; Gonçalez TT; Laycock ME; Pappalardo BL; Salles NA; Wright DJ; Chamone DF; Busch MP
    Transfusion; 2005 Nov; 45(11):1709-14. PubMed ID: 16271094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening.
    Kupek E; Petry A
    Rev Soc Bras Med Trop; 2014 Jul; 47(4):418-25. PubMed ID: 25229280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
    Seed CR; Cheng A; Ismay SL; Bolton WV; Kiely P; Cobain TJ; Keller AJ;
    Transfusion; 2002 Oct; 42(10):1365-72. PubMed ID: 12423522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.